Acne News and Research RSS Feed - Acne News and Research

Acne is a disorder resulting from the action of hormones and other substances on the skin's oil glands (sebaceous glands) and hair follicles. These factors lead to plugged pores and outbreaks of lesions commonly called pimples or zits. Acne lesions usually occur on the face, neck, back, chest, and shoulders. Although acne is usually not a serious health threat, it can be a source of significant emotional distress. Severe acne can lead to permanent scarring.
Researchers identify group of cells in brain that plays important role in Down syndrome

Researchers identify group of cells in brain that plays important role in Down syndrome

Researchers from UC Davis School of Medicine and Shriners Hospitals for Children - Northern California have identified a group of cells in the brain that they say plays an important role in the abnormal neuron development in Down syndrome. [More]
Doctors still prescribe patience as part of acne treatment regimen

Doctors still prescribe patience as part of acne treatment regimen

When it comes to treating acne, much has advanced medical practice, but patients are still prescribed patience as part of any treatment regimen, according to a nationally recognized expert on the skin condition that affects millions of teenagers in the U.S. each year. [More]
Personal rejection sensitivity linked with more severe BDD and depressive symptoms

Personal rejection sensitivity linked with more severe BDD and depressive symptoms

In a recent study, researchers at Rhode Island Hospital found that fear of being rejected because of one's appearance, as well as rejection sensitivity to general interpersonal situations, were significantly elevated in individuals with Body Dysmorphic Disorder (BDD). [More]
Metvix PDT now available at Odette Cancer Centre as additional treatment option for NMSC patients

Metvix PDT now available at Odette Cancer Centre as additional treatment option for NMSC patients

The Odette Cancer Centre at Sunnybrook Health Sciences Centre in conjunction with Galderma Canada are pleased to announce that Metvix PDT (Photodynamic Therapy), is now available at the Odette Cancer Centre in Toronto as an additional treatment option for patients with NMSC (non-melanoma skin cancer). [More]
Viewpoints: Expanding Hobby Lobby decision; the faux war on women; dispute over pelvic exams

Viewpoints: Expanding Hobby Lobby decision; the faux war on women; dispute over pelvic exams

The Supreme Court wasted no time in delivering a message to anyone who thought its Hobby Lobby ruling was limited to religious objections to coverage of purported abortion methods: You're wrong. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Galderma announces that the U.S. FDA granted Orphan Drug Designation status for the company's trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma plans to implement a clinical development plan, reinforcing its commitment to exploring new treatment options for rare diseases, as well as meeting the needs of all patients with skin diseases over the course of their lives. [More]
Prevalence of type 2 diabetes 5 times higher in women with PCOS

Prevalence of type 2 diabetes 5 times higher in women with PCOS

A leading expert on reproductive health says young women with Polycystic Ovary Syndrome (PCOS) have a startlingly higher risk of developing type 2 diabetes, even if young and not overweight. [More]
Third-line treatment options remain elusive for advanced, EGFR wild-type NSCLC

Third-line treatment options remain elusive for advanced, EGFR wild-type NSCLC

Phase II study findings show only marginal positive effects of third-line treatment with afatinib for advanced non-small-cell lung cancer in patients with wild-type epidermal growth-factor receptor tumour status. [More]

ClarityMD effective in clearing acne without irritation

Envy Medical, Inc., a leader in professional skincare products and services, is excited to announce the publication of a new study in the June issue of the Journal of Drugs in Dermatology (JDD) proving the superior efficacy of its highly innovative acne system – ClarityMD. [More]
Researchers examine effects of testosterone on women after menopause

Researchers examine effects of testosterone on women after menopause

Testosterone supplementation for women is a hot topic. A new pharmacokinetics study of a brand of testosterone cream for women approved in Western Australia has been published online in Menopause, the journal of The North American Menopause Society (NAMS). [More]
FDA grants orphan drug designation to EffRx Pharmaceuticals' EX404 for treatment of PCOS

FDA grants orphan drug designation to EffRx Pharmaceuticals' EX404 for treatment of PCOS

EffRx Pharmaceuticals SA, a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its proprietary metformin-based product candidate, EX404, for the treatment of pediatric polycystic ovary syndrome (PCOS). [More]
Celsus’ expert highlights serious side effects of topical corticosteroids

Celsus’ expert highlights serious side effects of topical corticosteroids

A 2013 Mayo Clinic study involving more than 140,000 patients revealed that skin disorders are the most common nonacute reason Americans seek health care. [More]
Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

Valeant Pharmaceuticals International, Inc. today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails. [More]

Envy Medical secures new growth capital from HCP & Company

Envy Medical, Inc., a leader in professional skincare products and services, announced today that it has secured new growth capital from HCP & Company, a middle-market private equity firm headquartered in Chicago. [More]
Women with PCOS more likely to experience chronic low-grade inflammation during pregnancy

Women with PCOS more likely to experience chronic low-grade inflammation during pregnancy

Women who have polycystic ovary syndrome - the most common hormone disorder in women of reproductive age - are more likely to experience chronic low-grade inflammation during pregnancy than counterparts who do not have the condition, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). [More]
5 super foods for attaining summer glow

5 super foods for attaining summer glow

Chances are you have seen glow-enhancing creams and serums lining the shelves of your local supermarket. Some are marketed as age- defying and promise to energize skin in a matter of days. [More]
Loyola's pediatric dermatologists highlight risks related to indoor tanning

Loyola's pediatric dermatologists highlight risks related to indoor tanning

Prom season is right around the corner and with that comes dress shopping and trips to the local tanning salons for many girls. [More]
PhotoMedex revenues decrease 12% to $50.1 million in first quarter 2014

PhotoMedex revenues decrease 12% to $50.1 million in first quarter 2014

PhotoMedex, Inc. reports financial results for the three months ended March 31, 2014 and announces LCA-Vision stockholder approval of PhotoMedex's previously announced acquisition of all outstanding shares of LCA-Vision, a leading provider of laser vision correction services under the LasikPlus brand. [More]

Emilia Group completes acquisition of Pharma Pac's strategic assets

Emilia Group is pleased to announce the recent acquisition of strategic assets of Pharma Pac LLC, an OTC private brand and contract manufacturer, located in DeKalb, MS. The new entity is named Emilia Resources LLC and will operate as a manufacturing company of pharmaceutical and cosmetic products that will combine with Emilia Personal Care's strength in sales, marketing, supply chain and customer service. [More]